贝伐珠单抗联合大体积再程放疗在化疗难治性高级别胶质瘤中的作用
多因素分析显示IDH1突变状态(P=0.041)和再程放疗前ECOG状态(P<0.001)与总生存期显著相关。结论认为贝伐珠单抗联合大体积再程放疗是复发高级别胶质瘤可行的晚期挽救选择,可延长生存且毒性低。
要点
- 大体积再程放疗联合贝伐珠单抗的中位PTV为145.3 cm³,总生存期7.8个月。
- IDH1突变状态和再程放疗前ECOG状态与总生存期独立相关。
- 4例疑似放射性坏死均发生于未 upfront 使用贝伐珠单抗的患者。
核心结论
- 贝伐珠单抗联合大体积再程放疗是复发高级别胶质瘤可行的晚期挽救选择,可延长生存且毒性低。
研究设计与样本
- 主要终点为再程放疗后中位生存期,采用Cox回归模型分析临床病理因素与生存的关联。
主要发现
- 全队列再程放疗后中位总生存期为7.8个月(95%CI 6.3-9.2个月),胶质母细胞瘤患者为7.5个月(95%CI 6.6-8.3个月)。
- 全队列多因素分析中,IDH1突变状态(P=0.041)和再程放疗前ECOG状态(P<0.001)与总生存期显著相关。
- 治疗后3个月,66.5%的患者ECOG评分为0-2。
- 共发生4例疑似放射性坏死,均见于未 upfront 使用贝伐珠单抗的患者。
关键数值与推荐
- 中位PTV为145.3 cm³。
- 全队列再程放疗后中位总生存期7.8个月(95%CI 6.3-9.2个月)。
- 胶质母细胞瘤患者再程放疗后中位总生存期7.5个月(95%CI 6.6-8.3个月)。
- IDH1突变状态与总生存期相关(P=0.041),再程放疗前ECOG状态与总生存期相关(P<0.001)。
临床怎么用
- 对于化疗难治性复发高级别胶质瘤,可考虑贝伐珠单抗联合大体积再程放疗作为晚期挽救治疗。
- 再程放疗前应评估ECOG状态和IDH1突变状态以辅助预后判断。
- 未 upfront 使用贝伐珠单抗的患者需警惕放射性坏死风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Current practice in re-irradiation (reRT) of previously treated high-grade gliomas (HGG) has generally been limited to small volume reRT with stereotactic procedures. Less evidence exists for large volume reRT involving treatment volumes equivalent to that used at initial diagnosis. The primary aim of this study was to investigate the outcome of large volume reRT delivered in combination with Bevacizumab (BEV) in patients with recurrent chemorefractory HGG. METHODS AND MATERIALS: Patients with HGG managed with reRT were entered prospectively into a database. Clinicopathological features were recorded including timing of reRT, use of BEV and Dosimetric data. Median survival following reRT was the primary endpoint and association with clinicopathological factors was assessed with cox regression models. RESULTS: Sixty seven patients in total were managed with reRT, 51 patients had glioblastoma and 16 had anaplastic glioma. The median PTV was 145.3 cm3. Median OS post reRT was 7.8 months (95% CI 6.3-9.2 months) in the total cohort and 7.5 months (95% CI: 6.6-8.3 months) for GBM patients. In multivariate analysis of the whole cohort, IDH1 mutation status (p = 0.041) and ECOG status prior to reRT (<0.001) were significantly associated with OS. In terms of safety and toxicity, the majority of patients (66.5%) were ECOG 0-2 three months after treatment. In total, four episodes of suspected radiation necrosis occurred, all in patients treated without upfront BEV. CONCLUSION: Large volume reRT with bevacizumab is a feasible late salvage option in patients with recurrent HGG and offers meaningful prolongation of survival with low toxicity.
引用
- Chan J, Jayamanne D, Wheeler H, et al. The role of large volume re-irradiation with Bevacizumab in chemorefractory high grade glioma. Clin Transl Radiat Oncol. 2020. PMID: 32195378. doi:10.1016/j.ctro.2020.03.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。